Lyell Immunopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Revenue	0.06	0.13	84.68	10.65	7.76	Upgrade
Revenue Growth (YoY)	-53.08%	-99.85%	695.15%	37.31%	1080.52%	Upgrade
Gross Profit	0.06	0.13	84.68	10.65	7.76	Upgrade
Selling, General & Admin	52.04	66.98	117.31	89.06	46.88	Upgrade
Research & Development	171.6	182.95	159.19	138.69	182.24	Upgrade
Other Operating Expenses	-4.65	-4.3	-4.86	-3.53	-1.65	Upgrade
Operating Expenses	218.99	245.63	271.64	224.22	227.48	Upgrade
Operating Income	-218.93	-245.5	-186.96	-213.57	-219.72	Upgrade
Interest & Investment Income	24.07	23.45	7.05	1.17	5.94	Upgrade
Other Non Operating Income (Expenses)	0.89	1.85	1.89	0.1	1.53	Upgrade
EBT Excluding Unusual Items	-193.98	-220.2	-178.02	-212.31	-212.26	Upgrade
Gain (Loss) on Sale of Investments	-13	-12.92	-5	-36.7	-	Upgrade
Gain (Loss) on Sale of Assets	-1.34	-1.51	-0.1	-1.21	4.88	Upgrade
Asset Writedown	-51.3	-	-	-	-	Upgrade
Other Unusual Items	3.8	-	-	-	2.9	Upgrade
Pretax Income	-342.99	-234.63	-183.12	-250.22	-204.47	Upgrade
Net Income	-342.99	-234.63	-183.12	-250.22	-204.47	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	3.58	Upgrade
Net Income to Common	-342.99	-234.63	-183.12	-250.22	-208.05	Upgrade
Shares Outstanding (Basic)	261	251	247	136	13	Upgrade
Shares Outstanding (Diluted)	261	251	247	136	13	Upgrade
Shares Change (YoY)	4.18%	1.58%	81.79%	925.18%	144.21%	Upgrade
EPS (Basic)	-1.31	-0.93	-0.74	-1.84	-15.69	Upgrade
EPS (Diluted)	-1.31	-0.93	-0.74	-1.84	-15.69	Upgrade
Free Cash Flow	-162.86	-166.38	-193.83	-191.75	-212.36	Upgrade
Free Cash Flow Per Share	-0.62	-0.66	-0.78	-1.41	-16.02	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-358906.56%	-188845.39%	-220.77%	-2005.31%	-2832.92%	Upgrade
Profit Margin	-562285.25%	-180486.15%	-216.24%	-2349.47%	-2682.49%	Upgrade
Free Cash Flow Margin	-266980.33%	-127984.62%	-228.89%	-1800.50%	-2737.94%	Upgrade
EBITDA	-199.3	-225.25	-168.94	-199.94	-215.43	Upgrade
EBITDA Margin	-	-	-199.49%	-	-	Upgrade
D&A For EBITDA	19.63	20.25	18.02	13.62	4.29	Upgrade
EBIT	-218.93	-245.5	-186.96	-213.57	-219.72	Upgrade
EBIT Margin	-	-	-220.77%	-	-	Upgrade

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q